Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Early Phase 1

7(87.5%)

N/A

1(12.5%)

8Total

Early Phase 1(7)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07243366Early Phase 1Not Yet Recruiting

Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis

Role: lead

NCT07201064Early Phase 1Not Yet Recruiting

A Study of SZ1003 Injection in Patients With Advanced Hepatocellular Carcinoma

Role: lead

NCT07192666Early Phase 1Not Yet Recruiting

Exosomes in Patients With Ocular Involvement of Sjögren's Syndrome

Role: lead

NCT07185139Early Phase 1Not Yet Recruiting

MSCohi-O Lenses for Ocular Involvement in Sjögren's Syndrome

Role: lead

NCT06952114Early Phase 1Not Yet Recruiting

A Study of Stem Cells Lenses in the coGVHD Subjects

Role: lead

NCT05845502Not ApplicableTerminated

Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma

Role: collaborator

NCT05856643Early Phase 1Recruiting

Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Ovarian Epithelial Carcinoma

Role: collaborator

NCT05686720Early Phase 1Unknown

Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer

Role: collaborator

All 8 trials loaded